10 Best Mid-Cap Growth Stocks to Buy According to Analysts

2. Legend Biotech Corp. (NASDAQ:LEGN)

Upside Potential: 138%

Number of Hedge Funds: 31

Legend Biotech Corp. (NASDAQ:LEGN) is a clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for cancer treatment. The company is best known for its lead product candidate, LCAR-B38M, an autologous CAR-T cell therapy targeting malignancies. Legend Biotech uses advanced technologies to enhance the efficacy and safety of its therapies, aiming to address significant unmet medical needs in oncology.

According to the company’s corporate presentation from February 2025, Legend Biotech Corp. (NASDAQ:LEGN) is rapidly progressing in building a strong product portfolio with 11 pipeline programs in hematologic malignancies, solid tumors, and autoimmune diseases. Encouragingly, the CARVYKTI therapy for multiple myeloma (a type of blood cancer) was the company’s most successful CAR-T launch to date, with $334 million in net trade sales in Q4 2024. Management envisions a $5.0 billion potential for CARVYKTI, which is highly supportive of the company’s future growth trajectory. To achieve this potential and expedite the development and commercialization of its therapies, Legend Biotech Corp. (NASDAQ:LEGN) has partnered with industry leaders Johnson & Johnson and Novartis, both renowned for their strong research and development expertise.